This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Antidepressant Nonadherence in Routine Clinical Settings Determined From Discarded Blood Samples

Ashlee M. Roberson, BA; Victor M. Castro, MS; Andrew Cagan, BA; and Roy H. Perlis, MD, MSc

Published: March 23, 2016

Article Abstract

Objective: Antidepressant nonadherence is common and represents a potentially modifiable risk factor for treatment nonresponse. We used a novel approach based on discarded blood samples from routine clinical blood draws to assess treatment nonadherence in a general clinical population.

Method: Individuals diagnosed with or without major depressive disorder (using ICD-9) and prescribed sertraline, citalopram, bupropion, or venlafaxine in January 2014 were identified by querying the electronic health record of 2 academic medical centers. Discarded blood samples from routine blood draws for 109 individuals within 14-90 days of treatment initiation were anonymized and then assessed for detectable serum antidepressant levels.

Results: Overall, 17% of samples lacked detectable levels of the index antidepressant. Individuals with public versus private insurance were more likely to have undetectable antidepressant levels (χ21 = 5.07, P = .02) as were those receiving shorter-term (< 90 days) prescriptions (χ21 = 4.03, P = .05).

Conclusions: In general, electronic prescribing data provided a reasonable proxy for actual antidepressant use. Additionally, up to 1 in 5 individuals prescribed an antidepressant may not be adherent, suggesting the need for further efforts to reduce treatment nonadherence.

Volume: 77

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF